Merck to develop mAb through $10.8b acquisition
European Pharmaceutical Review
APRIL 17, 2023
“I look forward to working with the Prometheus team to establish a new paradigm of precision treatment for immune diseases,” commented Dr Dean Y Li, President of Merck Research Laboratories. It binds both soluble and membrane associated human TL1A with high affinity and specificity. “By
Let's personalize your content